Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2009

BioFocus to Carry Out Medicinal Chemistry Work for Schering-Plough

  • BioFocus DPI signed a €2.8 million (about $4.12 million) drug discovery contract with Schering-Plough Research Institute (SPRI). The one-year collaboration will involve BioFocus DPI carrying out medicinal chemistry and supporting biology and ADME/PK services for multiple Schering-Plough drug discovery projects at two of SPRI’s European sites. The deal builds on a partnership that was established between the companies in May 2009 and expanded in September.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »